Clin Oncol | Volume 5, Issue 1 | Review Article | Open Access

SARS-CoV-2 Associated Thrombotic Coagulopathy

Ajaz Bulbul1,2,3* and Karl Koessler-Streiker4

1Department of Hematology and Oncology, Artesia General Hospital, Mexico 2Department of Hematology and Oncology, Texas Tech University Health Sciences Center School of Medicine, USA 3Department of Internal Medicine, The University of New Mexico, Mexico 4Burrell College of Osteopathic Medicine, Mexico

*Correspondance to: Ajaz Bulbul 

Fulltext PDF


The most common patterns of hematological complications in a critically affected COVID-19 patient are a subject of great interest currently. As more data comes to fray, we are beginning to understand the underpinnings of the myriad hematological effects of COVID-19 associated multiorgan affects. The hematological issues concerning COVID-19 include thrombosis (COVID Associated Coagulopathy: CAC), PIC (Pulmonary Intravascular Coagulopathy)/DIC, thrombocytopenia and leucopenia (lymphocytopenia). COVID-19 patients like all critically ill have variety of potential risk factors driving coagulopathy, including systemic infection, immobilization, mechanical respiratory ventilation, central catheterization [1]. It is this interplay of risk factors that makes management of COVID-19 associated coagulopathy complicated to understand and manage.




Bulbul A, Koessler-Streiker K. SARS-CoV-2 Associated Thrombotic Coagulopathy. Clin Oncol. 2020; 5: 1726.

Subscribe to Our Newsletter